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ABSTRACT
THE ROLE OF CYCLOSPORINE IN LIVER
DISEASE AFTER RENAL TRANSPLANTATION

Terry June Watnick
1987

The role of cyclosporine in liver disease after renal transplan¬
tation was evaluated.

In a retrospective analysis, liver function

tests (LFTs) were compared in cyclosporine-treated versus
azathioprine-treated renal transplant recipients.

In one type of

analysis, the incidence and causes of elevated transaminases (defined
as SCOT or SGPT greater than 41 IU/L on at least two consecutive
occasions) were determined in 19 cyclosporine-treated renal
transplant recipients versus 15 azathioprine-treated patients.
Forty-seven percent of the cyclosporine group (9 patients) versus 40%
(6 patients) of the azathioprine group (p=NS) developed abnormal
transaminases during the first 4 to 6 post-transplant months.

Peak

transaminase levels varied from one and one-half times to ten times
normal.

Cytomegalovirus (CMV) was the most frequently identifiable

cause of hepatic dysfunction (7 of 15 patients).
In another type of analysis, mean monthly SGOT, SGPT and total
bilirubin were compared in the two treatment groups.

There was no

consistent difference in mean SGOT or SGPT between the two groups.
Neither SGOT nor SGPT was correlated with serum trough cyclosporine
levels.

In contrast, total bilirubin levels tended to be higher,

although still within the normal range, in cyclosporine-treated
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patients versus azathioprine-treated patients.

The difference

was statistically significant in month 1 (.56 ± .04 vs .42 ± .05, p =
.04) and in month 3 (.68 ± .07 vs .44 ± .05, p = .01).

Both direct

and total bilirubin levels were correlated with cyclosporine trough
levels during the first two months when cyclosporine levels were
highest.
We conclude that cyclosporine therapy causes hepatic dysfunction
characterized by mild hyperbilirubinemia.

This effect is most

prominent in the early post-transplant period when cyclosporine
levels are highest.

If mean serum cyclosporine trough levels

(measured by high-pressure liquid chromatography) are kept below 200
ng/ml, however, this is of little clinical significance since
bilirubin levels remain within the normal range.

Because of the many

causes of viral hepatitis prevalent during the first six post¬
transplant months, elevated transaminases alone are not specific for
cyclosporine hepatotoxicity.

Multiple etiologies must be at least

considered before cyclosporine therapy is implicated in a case of
hepatic dysfunction.
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LITERATURE REVIEW
Cyclosporine, a potent immunosuppressive agent, is a cyclic
endecapeptide first isolated from two strains of the fungus
Tolypocladiurn inflatum Gams (2,3).

Cyclosporine is unique because,

unlike other immunosuppressive drugs, it acts directly on the
immunoregulatory responses of helper T cells without causing
generalized myelosuppression (1).
Cyclosporine is a lipophilic substance that can be given orally
or parenterally (3).

After oral administration, peak serum levels of

the drug are reached within 3 to 4 hours (4).

Even with a fixed

dosage regimen based on body weight, however, there is a wide
variation in blood concentrations of the drug due to erratic
absorption by the GI tract (4).

Because of its hydrophobic nature,

cyclosporine has a large volume of distribution and after chronic
administration tends to accumulate in the liver, kidney and fat
stores (4,7,8).

Thus, with continued use, there is a decreased

dosage requirement necessary to maintain constant serum cyclosporine
levels (9).

In whole blood, in the concentration range from 25 to

500 ng/ml, the uptake of cyclosporine by erythrocytes is about 50%
while leukocytes take up 10% to 20% (4).

Of the amount of drug

remaining in the plasma, 90% is protein bound mainly to lipoproteins
(8).

The uptake of cyclosporine by erythrocytes is a temperature

dependent process and when the temperature is lowered from 37°C to 21
*t, cyclosporine diffuses into blood cells (4).
Cyclosporine is metabolized in the liver by the cytochrome P
450
oxidase system and drugs interacting with this system can raise or
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lower blood levels of the drug (5).

Cyclosporine is excreted

primarily in the bile while only 6% of the parent drug and its
metabolites are excreted in the urine (4).

Not all the metabolites

of cyclosporine have been well characterized but they are thought to
have minimal immunosuppressive properties when compared with the
parent compound (5).

The toxicity of various metabolites has yet to

be determined but the major human metabolite of cyclosporine has no
nephrotoxicity in rats (7,12).
Because there is little correlation between dosage and blood
concentrations of cyclosporine and because toxicity is thought to be
concentration dependent, monitoring of drug levels has become
important in the clinical management of patients receiving
cyclosporine immunosuppression.
available for this analysis.

There are currently two methods

High-performance liquid chromatography

(HPLC) is expensive and labor intensive but is specific for the
parent compound (7).

The other method, a radioimmunoassay (RIA)

using a kit made by Sandoz, is inexpensive and can be used to perform
a large number of assays in a relatively short period of time (10).
The antibody provided in the kit, however, is nonspecific and detects
both the parent compound and some of its metabolites (10).

Thus,

cyclosporine levels determined by RIA can be 2 to 4 times higher than
those measured by HPLC and the difference can vary during the dosage
interval

(10).

In order to minimize this source of variation, most

centers monitor cyclosporine trough levels.

In general, cyclosporine

levels measured by RIA and HPLC parallel each other and either method
is adequate as long as the appropriate reference scale is used
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(13,14).

The one situation in which measurements by RIA may be

unreliable is in the setting of liver dysfunction.

Burckart et al.,

reported elevated RIA:HPLC ratios in pediatric recipients of
orthotopic liver transplants in conjunction with deteriorating
hepatic function, poor bile flow and elevated liver enzymes (15).
Since cyclosporine metabolites are excreted in the bile (with little
unmetabolized cyclosporine), cholestasis may cause elevated blood
levels of these metabolites detected by RIA but not HPLC (15).
For either method, whole blood, serum or plasma may be used.
Because cyclosporine can accumulate inside blood cells in a
temperature dependent fashion, levels in whole blood are always
higher than serum or plasma.

The ratio of whole blood cyclosporine

levels to serum or plasma is about 2:1 but may vary between patients
and according to hematocrit (7,10).

Many centers prefer to use whole

blood in assaying cyclosporine levels in order to avoid having to
equilibrate the sample at a set temperature before processing it.
This also makes it easier to compare data between centers.

Other

investigators, however, prefer to use plasma or serum levels because
they are not subject to variation in hematocrit and leukocyte number
and may more accurately reflect "free" concentrations (16).
As experience with cyclosporine has been gained, it has become
evident that drug levels necessary to achieve immunosuppression
without toxicity decrease with time after transplantation (38,39).
Data from several centers suggest that serum trough cyclosporine
levels (RIA) should be kept under 200 ng/ml especially in long-term
treated patients (7,9,14,38,39).
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Cyclosporine was first used in renal transplantation by Caine, et
al., in 1978 (11).

Since then cyclosporine has been shown to be just

as, if not more, effective than conventional immunosuppressive
therapy.

In three large, randomized prospective trials, one year

cadaver allograft survival rates in cyclosporine-treated patients
were 72% in the European multicentre trial, 80.4% in the Canadian
multicenter trial and 84% in the University of Minnesota trial.
One-year cadaver graft survival in patients treated with azathioprine
and prednisone at these centers was 52%, 64% and 79%, respectively
(17,18,19).

The difference was statistically significant only in the

first two trials.

Improved results with azathioprine in the last

center were probably due to the addition of other treatment
modalities such as anti lymphocyte globulin (ALG), pre-transplant
splenectomy and multiple transfusions.

Similar results with

azathioprine have been achieved by other investigators using similar
protocols (20,21).
All three groups have followed their patients for at least three
years and have demonstrated continued success with cyclosporine
(22,23,24).
In addition to improved graft survival, other advantages of
cyclosporine in comparison with azathioprine include a decrease in
the incidence of acute rejection, a decrease in the incidence of
infection, a steroid sparing effect and a decrease in time spent in
the hospital (18,19,25,26,37).
leukopenia (37).

Also, cyclosporine rarely causes

Cyclosporine is not without toxicity.

Minor but common side-

effects include gingival hyperplasia, hypertrichosis, gastrointes¬
tinal symptoms, fine tremor and paresthesias (3).

Lymphoprolitera¬

tive disorders, thought to be associated with Epstein-Barr virus
(EBV) infection, occur in cyclosporine-treated patients but the risk
is no greater than with conventional immunosuppressive therapy (3).
Lymphomas seen in the course of treatment with cyclosporine tend to
resolve with cessation of therapy (3).

The most attention has been

focused on the nephrotoxicity of cyclosporine especially in kidney
allograft recipients where it can make the diagnosis of rejection
difficult.

Renal dysfunction caused by cyclosporine can be acute or

chronic and generally responds to dosage reduction.

Metabolic

acidosis, with hyperkalemia and hypertension, may also be results of
cyclosporine induced nephrotoxicity (2,3).

Although renal allograft

recipients treated with cyclosporine consistently have higher serum
creatinines than azathioprine-treated patients, renal function does
not appear to deteriorate with time (23,25,26,27).
Of all the major side effects of cyclosporine, hepatotoxicity has
been the least well characterized.

In the initial pilot studies by

Caine, et al., in 1978 and 1979, it was noted that almost all
patients treated with cyclosporine had abnormalities in liver
function consisting of elevated bilirubin, alkaline phosphatase (AP)
and in some patients, transaminases as well

(11,28).

Since then it

has been observed that elevated AP in these patients is most often of
osseous origin and therefore probably not due to cyclosporine
hepatotoxicity (29,44,45).

Subsequent to these initial studies, investigators conducting
clinical trials have continued to note elevated liver function tests
(LFTs) in renal transplant recipients treated with cyclosporine.

The

incidence of hepatic dysfunction in these trials has ranged from 3.6%
to 42% (2,18,19,30,32,34,35,36).

It is unclear whether cyclosporine-

induced hepatotoxicity is manifested by elevations in bilirubin
alone, transaminases alone or both.

Some authors have described

hyperbilirubinemia as being characteristic of cyclosporine hepatotoxicity (34,35) but most have also noted accompanying elevations in
transaminases (2,18,31,33,36).

Differences may be due to a failure

in separating those patients with other reasons for hepatic dysfunc¬
tion.

It is generally agreed that cyclosporine-induced hepatotoxici-

ty tends to occur well within the first six post-transplant months
(2,31,34,36) and in most cases resolves with dosage reduction rarely
necessitating discontinuation of the drug (2,18,30,31,34,36).
The larger, randomized prospective clinical trials described
previously have compared liver function in cyclosporine-treated
patients and azathioprine-treated patients.

Najarian, et al., at the

University of Minnesota (19), found that the frequency of elevations
in serum bilirubin not due to infectious hepatitis was the same in
the cyclosporine group (17% of 121 patients) and in the azathioprine
group (15% of 109 patients).

Furthermore, between one and one and

one-half years post-transplantation, there was no statistically
significant difference in serum bilirubin or SGOT between the two
groups.

These findings are similar to those of the Canadian

Multicenter Trial (18) where approximately 4% of each group (103

cyclosporine patients and 107 azathioprine patients) had evidence of
hepatic dysfunction.

In the cyclosporine group, elevations in LFTs

(bilirubin, transaminases and gamma-glutamyl transpeptidase) were
associated with cyclosporine trough levels above 1000 ng/ml whereas
in the azathioprine group other causes were found (hypoxic liver
damage, CMV infection, trimethoprim-sulfamethoxazole toxicity and
cholelithiasis).

There was no difference in the mean level of

bilirubin or aspartate aminotransferase (AST) between the two
groups.

Cyclosporine-treated patients had a higher mean level of AP

but the enzyme was not fractionated.

It is thus unclear whether

elevated enzyme levels were of hepatic origin.
In the European multicentre trial (17,35), unlike the studies
cited above, there was a higher incidence of hyperbilirubinemia in
the cyclosporine group (20% of 117 patients) versus the azathroprine
group (3% of 115 patients).

At one year post-transplantation,

cyclosporine-treated patients had higher mean levels of bilirubin,
AST and AP than azathioprine-treated patients.
other studies, AP was not fractionated.

Unfortunately, as in

There was no difference in

the levels of alanine aminotransferase (ALT) or gamma-glutamyl
transpeptidase.
The increased incidence of hyperbilirubinemia in the European
trial versus the University of Minnesota trial may in part be due to
higher serum levels of cyclosporine in the former.

Although serum

drug levels were not reported in either study, in the University of
Minnesota trial, a lower initial dose of cyclosporine was used and
dosages were tapered more rapidly.

Other reasons for the disparity

-
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between these trials include possible differences in the frequency
with which LFTs were measured and in the methods used to identify
patients with causes of hyperbilirubinemia other than cyclosporine.
Because these papers did not focus on hepatotoxicity, neither of
these parameters was adequately described.
The observation of elevated LFTs in cyclosporine-treated patients
has prompted a few centers to examine the hepatotoxicity of
cyclosporine in a more systematic fashion.

Several factors alluded

to above have also made evaluation of these reports difficult.

There

are many causes of abnormal liver function tests in the immediate
post-transplant period, as will be discussed in detail later.

In

many studies it was unclear how cyclosporine-induced hepatotoxicity
was distinguished from other causes of hepatitis.

Most authors

focused on abnormalities in one enzyme, bilirubin, without looking at
transaminases and did not specifically state how often LFTs were
measured.

This could be important especially in the early

post-transplant period when cyclosporine levels tend to be high and
episodes of transient hepatotoxicity might be missed.

Lastly,

because centers used different definitions of hepatotoxicity and
different techniques to measure cyclosporine levels, it was difficult
to compare results.
One set of reports concentrated on the hyperbilirubinemia
characteristic of cyclosporine-induced hepatotoxicity.

Laupacis, et

al., looked at 21 cadaveric renal transplant recipients treated with
an initial cyclosporine dose of 17.5 mg/kg/day further adjusted to
achieve serum trough levels (by RIA) of 100-400 ng/ml and two-hour
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post dose levels of 400-1000 ng/ml (41).

All patients had

cyclosporine levels and bilirubin levels measured daily in the
hospital.

Four patients (19%) had one episode of hyperbilirubinemia

(serum bilirubin greater than 1.0 mg/dl for 3 days with no other
apparent cause) within two weeks of transplantation lasting 3 to 6
days.

A causal relationship was observed between hyperbilirubinemia

and cyclosporine levels in these patients.

That is, cyclosporine

trough levels and 2-hour post-dose levels rose prior to the serum
bilirubin and fell, with dose reduction, prior to normalization of
bilirubin.

The authors conclude that cyclosporine-induced hyper¬

bilirubinemia occurs with trough and 2 hour post-dose cyclosporine
levels greater than 400 ng/ml and 1000 ng/ml respectively.

In this

study, although cyclosporine and bilirubin levels were documented
carefully while patients were in the hospital

(probably at least two

weeks), there is no mention made of how often LFTs were measured
after this period and whether or not there were any other LFTs
elevated.

Also, it is not stated which other causes of hyperbili¬

rubinemia were excluded.
Loertscher, et al., studying only 8 patients receiving
cyclosporine (17 mg/Kg/day for 14 days with subsequent monthly
reductions of 2 mg/Kg/day) found that 5 patients developed simul¬
taneous increases in bilirubin and cyclosporine within 5 days of
transplantation (40).

Two additional patients, however, had hyper¬

bilirubinemia without elevations in cyclosporine trough levels later
in the post-transplant course.

One patient had a high cyclosporine

trough level without hyperbilirubinemia.

These authors conclude that

10

hyperbilirubinemia is caused by cyclosporine therapy but is indepen¬
dent of serum drug levels.
Klintmalm, et al., obtained similar results in a larger group of
66 recipients of cadaveric kidneys who recieved 17 mg/Kg/day of
cyclosporine for at least 8 weeks post-operatively (42).

Eleven of

13 (19.6%) patients who displayed hyperbilirubinemia (bilirubin
greater than 2.0 mg/dl) developed it early between 2 weeks and 2
months post-transplant when doses in those patients were still high
(mean 17.7 ± 1.1 mg/Kg/day).

Three patients had hyperbilirubinemia

greater than 6 months post transplant when cyclosporine doses were
less than 10 mg/Kg/day.

No cyclosporine levels were available but

all cases resolved with dosage adjustments.

One-half of the patients

had normal transaminases (SGOT and SGPT) while in the other half
there were elevations to 3 times normal, suggesting that these
enzymes are not specific for cyclosporine-induced hepatotoxicity.

AP

levels in patients with hyperbilirubinemia were normal or slightly
above normal.

It was mentioned that one of the 13 patients was HBsAg

positive prior to transplantation while 7 patients were on other
drugs with hepatotoxic potential

(cimetidine, isoniazid).

these drugs was changed during toxic episodes.

None of

It was not stated

whether other causes of viral hepatitis were investigated.
Another paper by Klintmalm, et al., also suggests that bilirubin
is the more important parameter in reflecting hepatotoxicity (39).
Of 48 renal transplant recipients treated with cyclosporine (15
mg/Kg/day and then tapered), 18 had isolated increases in ALT while 7
had increases in ALT and bilirubin (ALT greater than 25 umol/L,
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bilirubin greater than .70 ukat/L with no other possible explana¬
tion).

Isolated increases in ALT

occurred during the first month in

15 patients and between 2 and 12 months in 3 patients.
cyclosporine plasma level

The mean

(RIA) was not higher in these patients and

elevations resolved within 2 weeks without dosage adjustments.

Of

the 7 patients (14.6%) with increases in ALT and bilirubin, 5
occurred in the first post-transplant month.

The mean cyclosporine

trough plasma level was higher during these episodes (732 ± 102
ng/ml) than during normal liver function (226 ± 26 ng/ml, p < .01).
The authors conclude that increases in ALT alone are of little
clinical significance while increases in bilirubin and ALT require
dosage adjustment for resolution.
The results of Keown, et al., confirm the association between
cyclosporine levels and hyperbilirubinemia (9,43).

Of 72

cyclosporine-treated patients (dose not stated), 6 patients (8.3%)
developed hyperbilirubinemia (bilirubin greater than 1.0 mg/dl) all
during the first three post-transplant weeks.

Serum cyclosporine

levels (by RIA) rose prior to the onset of hyperbilirubinemia, from
65 ± 66 ng/ml to 630 ± 112 ng/ml.
dosage was decreased.

All cases resolved after the

Linear regression analysis showed that serum

bilirubin was directly correlated with cyclosporine trough level
2
(r - .58, p = .001).
It was not stated whether other LFTs were
elevated as wel1.
Findings in recipients of other organs also point out the
significance of hyperbilirubinemia.

Schade, et al., retrospectively

studying 30 cyclosporine-treated recipients of heart transplants,
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found that serum bilirubin reached a peak elevation, 2.5 times normal
at about 2 weeks post-transplant while pre- and post-transplant SGOT,
SGPT and AP were not significantly different (48).

Interestingly, in

11 subjects, fasting serum bile salt levels were elevated (despite
normal AP) indicating pronounced cholestasis.
blood level

The mean cyclosporine

(HPLC) in these patients was 474 + 47 ng/ml and there was

no correlations between drug levels and serum bilirubin or bile salt
levels.
Atkinson, et al., retrospectively studying bone marrow transplant
recipients, found that 10 of 21 patients had cyclosporine associated
hyperbilirubinemia (49).

Eight additional patients had other causes

for their elevated bilirubin levels, for example, acute graft-versushost disease of the liver, sepsis and hemolysis.

It was not clear

that viral hepatitides such as cytomegalovirus (CMV) were ruled out.
Cyclosporine-induced hyperbilirubinemia was also associated with an
increase in ALT (mean = 109 ± 47 IU/L) but AP levels were only
minimally elevated.

Cyclosporine trough levels were correlated with

bilirubin levels (correlation coefficient = .36).

The mean day of

onset of hepatotoxicity was 18.5 ± 18 with a mean duration of 72 ±
47.5 days.

This prolonged hepatic dysfunction in the face of

cyclosporine dose reductions suggests that perhaps patients with
viral hepatitis may have been included in this group.
Only the group in Birmingham has made an attempt to compare LFTs
in cyclosporine- and azathioprine-treated patients (44,45).

In a

randomized, prospective study, 35 patients were treated with a
cyclosporine dose of 15 mg/Kg/day with reduction to 12 mg/Kg/day at 1

13

month post-transplant; 31 patients were treated with azathioprine
(44).

At least some patients had LFTs measured at weekly intervals

for the first 12 post-transplant weeks (45).

Mean bilirubin levels

were significantly higher in the cyclosporine-treated patients for
the first 3 post-transplant months but hyperbilirubinemia was
uncommon.

AST levels were significantly higher in the cyclosporine

group only during the first post-transplant month.

Mean AP levels

were significantly higher in cyclosporine-treated patients at all
times but in only one patient was it due to the hapatic isoenzyme.
Five patients (14%) in the cyclosporine group and nine patients (29%)
in the azathioprine group developed abnormalities in bilirubin or
transaminases (bilirubin greater than 22 umol/L, AST greater than 35
IU/L).

In the cyclosporine group, elevations were due to CMV (2

patients), herpes simplex (HSV), congestive cardiac failure and
possible cyclosporine toxicity although in this patient, LFTs did not
normalize with dose reduction.

In the azathioprine group the reasons

were sepsis (3 patients), viral encephalitis, hepatitis B virus (HBV)
infection and 4 cases were unexplained, possibly due to azathioprine
or isoniazid.

The authors conclude that infection was the most

common cause of liver dysfunction following renal transplantation and
that cyclosporine has no marked hepatotoxicity.

Because bilirubin

was higher in the cyclosporine group (although still within the
normal range) during the first 3 months, however, it was concluded
that cyclosporine is responsible for subclinical hepatic dysfunc¬
tion.

One possible reason for the different conclusions reached by

these authors is the frequency with which LFTs were measured.
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Although the timing of elevated LFTs was not specifically stated, it
is possible that the early hyperbilirubinemia that occurred within
the first post-transplant days in other studies was missed.

In

addition, the initial cyclosporine dose administered by the
Birmingham group was lower than in the studies discussed previously.
Only two centers have found elevated transaminases to be
indicators of cyclosporine-induced hepatotoxicity.

In an abstract,

Maddux, et al., reported their study of 46 renal transplant
recipients treated with cyclosporine (12-14 mg/Kg/day for 7 to 14
days followed by titration to whole blood trough levels of 400-800
ng/ml (46).

Six patients were excluded because of insufficient

follow-up, sepsis or viral hepatitis.

Of the remaining 40 patients,

16 (40%) had elevated LFTs, mainly SG0T (62%) and SGPT (88%), an
average of 41 days post-transplant.
rubinemia.

Only 1 patient had hyperbili¬

Patients with elevated LFTs had higher whole blood trough

levels (920 ng/ml) than patients with normal LFTs (447 ng/ml, p <
.05) and elevations resolved after dosage reduction.

In this study,

it is not stated how often LFTs were measured and it is possible that
early

hyperbilirubinemia was missed.

Alternatively, not only were

lower doses of cyclosporine used initially, but trough levels were
monitored so that hyperbilirubinemia due to early elevations in
cyclosporine levels may have been avoided.

Patients with sepsis and

viral hepatitis were excluded but which types of hepatitis were
tested for, i.e., CMV, was unclear.

Although elevations in LFTs

resolved with dosage reduction, improvement occurred in a mean time

15

of 60 days.

This could easily have been due to resolution of another

disease process.
The most comprehensive series reported in the literature is that
of Lorber, et al., who followed 466 cyclosporine-treated renal
transplants (47).

Because of its depth, this study deserves detailed

consideration.
Several cyclosporine protocols were used and many patients
received a continuous IV cyclosporine infusion (3 mg/Kg) during the
first 48 post-transplant hours.
was resumed and tapered.

Oral cyclosporine at 14 mg/Kg/day

After 14 days, the cyclosporine dose was

adjusted to maintain serum trough levels of 50-200 ng/ml

(RIA).

Hepatoxicity was defined as bilirubin greater than or equal to 1.5
mg/dl and/or SGOT or SGPT greater than or equal to 50 IU/L when other
potential reasons were excluded.

Isolated elevations in AP or LDH

were not considered to represent hepatotoxicity.
managed by decreasing the

Hepatotoxicity was

cyclosporine dose to achieve trough levels

less than or equal to 100 ng/ml.
Of 466 patients, 228 or 49% had at least one episode of elevated
LFTs.

Of those patients with hepatic dysfunction, 110 (48%) had

hyperbilirubinemia, 108 (47%) had an elevated SGOT and 167 (73%) had
an elevated SGPT.

Only 1 patient had an isolated abnormality while

most (140/228) had elevations in bilirubin or transaminases with
increases in AP and LDH.

Most patients (187/228) had isolated

episodes of hepatotoxicity while 41 patients had recurrent or
persistent elevations in LFTs.

The mean cyclosporine level was 226 +

17 ng/ml in hepatotoxic patients but was not compared to the level in
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those patients with normal LFTs.

Hepatotoxic patients did have

increased bioavailability and decreased cyclosporine clearance when
compared with the other patients.

In 214 of 228 patients (94%)

hepatoxotoxicity began during the initial 90 post-transplant days. In
fact, 50 patients exhibited elevated LFTs during the 48 hours of IV
infusion and 61% of hepatotoxic episodes began within the first seven
days when cyclosporine doses were highest.

Dosage reduction resulted

in resolution in 81% of the patients including all 14 patients whose
elevated LFTs began after 90 days.
The incidence of hepatotoxicity detected in this series exceeds
that found by any other group.

There are several possible reasons.

First, unlike other protocols, patients were treated with continuous
infusions of cyclosporine, presumably leading to higher levels of the
drug.

In fact, almost 1/4 of patients with hepatotoxicity

experienced it during this period.

Although not explicitly stated,

LFTs were probably measured daily in the hospital allowing for
increased detection of abnormalities.

It would be interesting to

know whether elevations occurring during the first post-transplant
week were predominantly hyperbilirubinemia, as found in other
studies.

Lastly, it is unclear from this paper how many patients may

have had other causes for abnormal LFTs.

For example, of those

patients with hepatotoxicity, 16 had a history of polycystic disease,
16 had a history of "hepatitis," 4 had cholelithiasis, 3 had peptic
ulcer disease and 3 had pancreatitis.

Although it was stated that

these problems were corrected prior to transplantation, they could
conceivably continue to cause elevated LFTs and additional
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investigation might be necessary to rule this out.

Furthermore, it

would not be at all inconsistent to assume that the 32 patients with
recurrent or persistent LFT abnormalities had non A- non B-hepatitis
which is the most common cause of hepatitis in renal transplant
recipients (51,62).

In addition, although the authors state that

patients with viral hepatitis were excluded, it might be useful to
know which viral infections were tested for in these patients, i.e.,
CMV, EBV, HBV, HSV.
All of the other studies previously discussed have concluded that
cyclosporine-induced hepatotoxicity is without sequelae.

Lorber, et

al., however, found that 11 (5%) cyclosporine-treated patients with
hepatotoxicity developed biliary calculous disease detected between 8
and 33 months post-transplant.

Nine of the patients previously had

recurrent or persistent cyclosporine "hepatotoxicity."

The authors

suggest that cyclosporine hepatotoxicity may be linked to biliary
calculous disease.

No cholelithiasis was seen in 279 azathioprine-

treated patients at the same institution.

These suggestions must be

regarded cautiously since the incidence of biliary calculous disease
in cyclosporine-treated patients without hepatotoxicity was not
reported.

As the authors suggest, longer follow-up of this cohort is

necessary.
In sum, the incidence of cyclosporine-induced hepatotoxicity has
varied depending on the definition applied and the rigor with which
abnormalities have been searched for.

Authors that have obtained

LFTs frequently in the early post-transplant period when cyclosporine
levels vary widely have found a high incidence of hepatotoxicity.
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There seems to be general agreement that cyclosporine liver toxicity
during this period is manifested by elevations in serum bilirubin
often associated with increases in transaminases.

These

abnormalities which are directly related to blood levels of the drug
resolve with dosage reduction.

A minority of patients can develop

hyperbilirubinemia after this period which is still reversible with
dosage reduction.

Often, however, serum cyclosporine levels are not

absolutely elevated.
Elevations in LFTs after the first few post-transplant weeks have
been attributed to cyclosporine but the analysis of many authors has
been confounded by a failure to consider the many other causes of
post-transplant hepatitis.

Post-transplant hepatitis is a common

phenomenon and long before the advent of cyclosporine, liver
dysfunction was noted to occur in 7 to 67% of renal transplant
recipients with 6 to 16% of these patients developing chronic
hepatitis (50,51).

The significance of these figures cannot be

underestimated since in one study the most common cause of mortality
in renal transplant recipients with grafts surviving more than 5
years was chronic liver disease (52).
by extrahepatic sepsis (52).

Death was usually precipitated

Conversely, patients exhibiting chronic

liver disease were found to have decreased survival when compared to
patients without elevated LFTs (51,53).

It is important to state

that all the studies of liver disease in renal transplant recipients
were done prior to the cyclosporine era.

The complexities inherent

in assigning an etiology to elevations in LFTs after renal
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transplantation are best appreciated by a brief consideration of the
many possible causes of post-transplant hepatitis.
Although at one time HBV infection was thought to play a major
role in post-transplant hepatitis, the importance of this agent has
waned due to the introduction of tests to screen banked blood for HBV
surface antigen (HBsAg) (51,62,63,66,69).

In one large series, for

example, Ware, et al., found that HBV accounted for only 10% of liver
disease detected in renal transplant recipients (62).

HBV is still

thought to be an important factor in chronic hepatitis (53,70),
however.

HAV appears to play no role in the development of

post-transplant hepatic dysfunction (51,62).
Clearly, then, post-transplant hepatitis in the majority of cases
is due to non A-non B hepatitis.

Although many agents have been

implicated as the cause of non A-non B hepatitis, in most cases of
post-transplant hepatitis it is impossible to find an etiology
(51,53,62,63,65,66).

This has lead some authors to conclude that the

most common cause of hepatitis (especially chronic hepatitis) is
transfusion associated, viral, non A-non B hepatitis (51,62).
In the cases where an etiology can be assigned, CMV is the most
frequently implicated agent.

CMV infection is ubiquitous in renal

transplant recipients with active infection rates between 43 and 92%
(55).

The onset of a large number of CMV infections (as well as CMV

hepatitis) occurs within the first 2 1/2 months and almost all occur
by the fourth post-transplant month (54,56,57,58,59,61).

Primary CMV

infection occurs in patients who have no serologic evidence of prior
CMV exposure and is thought to be primarily transmitted by an

-
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allograft from a seropositive donor (54,55).

Secondary CMV disease,

which is more common, happens when the recipient who is seropositive
pre-transplant reactivates latent CMV, probably as a result of
immunosuppresive medications (54,55,57,60).

Active CMV infection is

asymptomatic in about two-thirds of cases while only 2%-3% suffer
fulminant, disseminated terminal disease (54,56,57,59,61).

Those

patients with symptomatic CMV can exhibit a syndrome characterized by
fever, leukopenia, fatigue, pneumonitis and hepatitis (54,55,56).

In

several large studies of liver disease in renal transplant
recipients, CMV has been implicated in 18 to 30% of cases (51,62,
63).

Conversely, about 15% of patients with active CMV infection

develop hepatitis (55,58,61).

Liver dysfunction is more common in

patients with primary CMV infection (55).

The degree and extent of

liver function abnormalities correlates with the magnitude of CMV
titer rises and with the general severity of the disease (56,64).
CMV hepatitis has been mostly associated with elevations in trans¬
aminases, particulary SGOT (56,61).

CMV hepatitis in the renal

transplant recipient tends to be a transient, self-limited disease
but fulminant cases progressing to hepatic failure and death have
been reported (62,63,64,65).

Several authors have tried to implicate

CMV as a cause of chronic HBsAg negative hepatitis in renal
transplant recipients since liver dysfunction due to CMV has been
reported to last as long as 20 weeks (56,62,64,65).

Although hepatic

dysfunction and CMV infection often occur concurrently, as Ware, et
al., point out, care must be taken in implicating CMV.

Because CMV

infection is so common, there is always the possibility that these

&
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events overlapped by chance (62).

If, however, the onset of liver

disease is accompanied by a characteristic febrile illness with
positive cultures and subsequent seroconversion, CMV can be assigned
as the cause with some certainty (62,65).
In contrast to CMV, other members of the herpes virus family EBV, HSV and herpes zoster (HZV) - are thought to play a small role
in post-transplant hepatitis with sporadic cases reported in several
studies (62,63,65,66).

This may in part be due to the fact that

these viruses are not tested for on a routine basis.

As in the case

of CMV, a large number of renal transplant patients are seropositive
for these herpes viruses prior to transplantation and often latent
virus can be reactivated as evidenced by seroconversion (50,54,61,62,
64,67,68).

These viruses also have their onset mainly in the first

six post-transplant months (54).

In the case of HSV and HZV,

infections are usually cutaneous in nature but can disseminate
causing fulminant terminal hepatitis (50,54,62,63,66).

In the case

of EBV, infection is most notable for its association with lymphoproliterative disorders but may also cause a CMV-like syndrome with
acute hepatitis (54,67,68).

To complicate diagnosis further, there

has been a suggestion that other herpetic infections can mimic CMV
since in some patients there may be concurrent rises in antibodies to
CMV and EBV, HSV or HZV along with the symptoms characteristic of CMV
(67,68,74).
In addition to the multiple viral causes of post-transplant
hepatitis, renal transplant patients often receive a number of
potentially hepatotoxic drugs including alpha-methyldopa, isoniazid.

-

acetaminophen, furosemide and
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hydralazine (50).

In one study,

patients recieved a mean of seven proven potentially hepatotoxic
drugs (71).

Prior to the advent of cyclosporine, in fact,

azathioprine was thought by many to be an important etiologic factor
in post-transplant liver disease (65,66,71,72).

Azathioprine can

cause a dose-related cholestatic picture and many series have
reported cases of liver dysfunction which reversed with azathioprine
reduction or discontinuation (51,62,65,69).

Despite this, the

overwhelming consensus is that azathioprine and drugs in general are
a minor cause of acute hepatic dysfunction and are of no importance
in chronic hepatitis (51,62,63,65,66,69,71,72).
Aside from viruses and drugs, other possible causes of abnormal
LFTs will only be mentioned and include congestive cardiac failure,
diabetes mellitus, polycystic disease, biliary tract disease and
ethanol abuse (50,73,76).
This brief review is sufficient to underscore the fact that
multiple etiologies must be at least considered before cyclosporine
toxicity can be definitively implicated in a case of abnormal LFTs.
This is especially true of the viral hepatitides which tend to occur
during the same time period as cyclosporine hepatotoxicity, during
the first 4 to 6 post-transplant months.

Unfortunately, most of the

studies that have examined cyclosporine hepatotoxicity have not
detailed which other causes of hepatitis were ruled out, making the
results difficult to interpret.

- 23 -

PURPOSE
The purpose of this retrospective study was to examine the role
of cyclosporine in liver disease occurring during the crucial first 6
months after renal transplantation.
addressed.

Several important questions were

First, are all cases of liver dysfunction that occur

during cyclosporine therapy due to the drug itself?

Second, do

elevated LFTs occur more fequently with cyclosporine than with
azathioprine immunosuppression?
cyclosporine hepatotoxicity?

Lastly, which LFTs, if any, reflect

Since liver disease is an important

cause of mortality in long-term survivors of renal transplantation,
answers to these questions may help to elucidate whether cyclosporine
will aggravate the course of this disease.
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MATERIALS AND METHODS
Cyclosporine was introduced at Yale in November of 1983.

Up

until January, 1985 it was used with steroids only in high-risk renal
transplant recipients, i.e., diabetics, recipients greater than 50
years of age, recipients of second and third grafts.

Since January,

1985, cyclosporine has been used in all recipients of cadaveric
kidney transplants.

Patient Population
Liver function tests (LFTs) and cyclosporine levels (where
applicable) were analyzed for all patients (n=56) receiving a renal
transplant at Yale-New Haven Hospital between August, 1983 and April,
1985.

In order to be included, patients had to have had bimonthly

LFTs consisting of SGOT and/or SGPT, for the first two months
following transplantation and monthly LFTs thereafter for at least
two additional months.
they were available.

Bilirubin levels were also analyzed whenever
AP levels were not examined because

fractionation to determine percent bone activity was not routinely
performed.

Patients were

excluded from this study if they had

chronic elevations in LFTs due to known liver disease prior to
transplantation.

For the purposes of this study, patients were

followed for a minimum of four months and a maximum of six months.
Patients were assigned to the cyclosporine treatment group or the
azathioprine group depending upon which drug was used during the
second through sixth post-transplant months.

Thus, patients in the
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cyclosporine-treated group had to have been started on the drug
within one month of transplantation and maintained on it for at least
four consecutive months; likewise for the azathroprine-treated
group.

Four patients were switched from azathioprine to cyclosporine

between one and four months post-transplant.

These patients could

not be included in either group and were excluded from analysis,
leaving 52 patients.
Of 25 cyclosporine-treated patients, six were excluded.

Two

patients had chronically elevated LFTs prior to transplantation - one
presumed second to polycystic liver disease and the other thought
second to non A-non B hepatitis.

Four additional patients had

insufficient follow-up (one patient died two months post-transplant,
one left treatment AMA and two did not have a sufficient number of
LFTs measured.)

One patient who was included in the cyclosporine

group was also maintained on low-dose azathioprine.

There was a

final total of 19 cyclosporine-treated patients included for
analysis.
Of 27 azathioprine-treated patients, twelve were excluded because
there were an insufficient number of LFTs measured during the
follow-up period.

Four patients had one set of LFTs missing but had

good follow-up in subsequent months and were included in the study.
Another patient that was included had only one set of LFTs measured
in the second post-transplant month, no LFTs in the third month, but
had increased LFTs in the fifth month.

A total of 15 patients thus

comprised the final azathioprine treatment group.
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Drug Dosages
Those patients treated with cyclosporine from the day of
transplantation received a loading dose of 15 mg/kg orally or .5
mg/kg intravenously on the day of surgery.

Thereafter patients

received a dose of cyclosporine once or twice per day to approximate
a serum trough level of 50-150 ng/ml.

Cyclosporine levels were

measured daily while the patient was in the hospital and weekly
thereafter.

Cyclosporine-treated patients were given oral prednisone

begun at 2 mg/kg/day and tapered to .25 mg/kg/day over the first
month.
Patients in the azathioprine group received 2 mg/kg/day with the
dosage adjusted for leukopenia and infection.

Patients also received

prednisone begun at 4 mg/kg/day tapered to .5 mg/kg/day over the
first post-transplant month.
Rejection in all patients was confirmed by renal biopsy and
treated with pulse steroids (500 mg solumedrol x 3).

If the

rejection was steroid resistant, the patient was then treated with
two to three weeks of Upjohn Anti thymocyte globulin (ATG), 15
mg/kg/day, or Ortho monoclonal antibodies against 0KT3 cells for ten
days.

Definitions and Data Analysis
Elevated LFTs were defined as an SGOT or SGPT of greater than 41
on two consecutive occasions.

Total serum bilirubin levels greater

than 1.5 mg/dl were considered abnormal.

For each increase in LFTs

within the first six post-tranplant months, the patient's hospital
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and outpatient records were examined for laboratory data, relevant
symptomatology, medications and other pertinent clinical information.
Most increases in LFTs were followed up with serum testing for
HBV and anti-EBV antibody levels.

In addition, serum CMV antibody

titers along with urine and saliva CMV cultures were obtained monthly
post-transplant for six months on all patients and more frequently if
LFTs were elevated.
A number of criteria were used in assessing the cause of an
elevation in LFTs.

A rise in LFTs was considered to be due to CMV

infection if the rise was associated with or followed by serocon¬
version or a four-fold rise in CMV antibody titer and/or positive CMV
cultures.

The infection was considered to be primary if the patient

was antibody negative pre-transplant and due to reactivation if the
patient had been antibody positive (antibody titer greater than
1:8).

If a positive serology and elevated LFTs were associated with

fever (temperature elevation above 100 F for at least two days)
3
and/or a depression in WBC (3500 cells/mm for at least two days),
this was taken to be further evidence of CMV infection.
An elevation in LFTs was considered to be due to an EBV infection
if anti-EBV viral capsid antigen (VCAG) titer was greater than 1:160
and if the anti-EBV early antigen (EAG) titer was greater than 1:20.
A patient was considered to have an acute HBV infection if the
increase in LFTs was associated with an HBV screen positive for HBsAg
and/or IgM antibodies against HBV core antigen.

A diagnosis of non

A-non B hepatitis was entertained if the patient had persistent
elevations in LFTs, especially SGPT, in the absence of the other
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viral causes mentioned above.

If the elevation was transient,

however, and associated with a clinical syndrome consistent with a
viral illness (fever, leukopenia) it was designated as "other viral."
An elevation in LFTs was considered to be due to drug toxicity if
it was associated with an elevated drug level and if the LFTs
decreased with decreasing drug levels or after the drug was
discontinued.
Several other causes of elevated LFTs were considered such as
passive liver congestion due to cardiac failure, sepsis, fatty liver
associated with diabetes mellitus and ethanol abuse.
In addition to the analyses described above, average monthly
SGOT, SGPT and total bilirubin were compared in cyclosporine-treated
patients versus azathiprine-treated patients.

An attempt was made to

correlate cyclosporine trough levels with SGOT, SGPT and bilirubin.
Graft loss was defined as nephrectomy, return to dialysis or
death of the patient.

Laboratory Methods
LFTs were measured using the EPOS autoanalyzer.

Six patients had
0

transaminases measured on serum samples stored at -20 C for anywhere
from 5 to 22 months after collection.

Four patients had one sample

and two patients had two samples assayed after storage in this
fashion.

Three patients belonged to the cyclosporine group and three

to the azathioprine group.
by HPLC.

Serum cyclosporine levels were determined

The methods used have been described previously (16).
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Serum CMV titers were measured by a complement fixation technique
that detects mainly IgG antibody to CMV.
was considered positive.

An antibody titer above 1:8

Techniques used to process urine and saliva

CMV cultures are described elsewhere (75).
A hepatitis B screen consisted of HBsAg titer, anti-HBsAg titer
and anti-HBV core titer.

If a patient was found to be positive for

anti-HBV core antibodies, it was determined whether or not they were
IgM in type.

These tests were all performed via an Elisa technique

using kits from Abbott Laboratories.
Serum antibodies against EBV antigens were measured using
indirect immunofluorescence.

If a patient had an anti EBV VCAG titer

greater than 1:160, antibody against EBV-induced early antigens was
measured.

A titer greater than 1:20 was indicative of acute EBV

infection.

Statistical Analysis
Statistical analysis was carried out using SASS and Clinfo series
of programs.

Groups were compared using the Student's T-test and Chi

square analysis.

Linear regression analysis was also employed.

results are expressed as the mean t SEM.

All

P values less than or equal

to .05 were considered statistically significant.
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RESULTS
Baseline characteristics of the cyclosporine treatment group and
the azathioprine treatment group are compared in Table 1.

As

expected, due to the initial use of cyclosporine only in high-risk
patients receiving cadaveric grafts, cyclosporine-treated patients
tended to be older and a larger percentage received cadaveric
transplants when compared with azathroprine-treated patients.

Six

and 12 month graft and patient survival tended to be higher in the
azathioprine-treated group but the difference was not statistically
significant.

Again, this is probably due to the initial use of

cyclosporine in high-risk renal transplant recipients.

When all

patients with liver disease (including two cyclosporine-treated
patients with known liver disease prior to transplantation) were
considered together, their one year survival was 82% compared with
100% for those transplant recipients without liver disease (p = .1).
Graft survival was 76% vs. 97%, respectively (p = .04).

Nineteen

cyclosporine-treated patients and 15 azathioprine-treated patients
form the basis for the rest of this report.
The frequency of elevated LFTs in each group was similar.
Forty-seven percent (9 patients) of the cyclosporine group versus 40%
(6 patients) of the azathioprine group (p = .74) developed abnormal
transaminases during the first 4 to 6 post-transplant months.

Peak

transaminase levels varied from one and one-half to ten times
normal.

Although serum bilirubin levels were not obtained regularly,

no patient had hyperbilirubinemia in the absence of elevated SG0T
and/or SGPT.
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Each patient with elevated LFTs had an identifiable cause for
their hepatic dysfunction.

Graphs of post-transplant transaminases

including pertinent clinical and laboratory data for each patient
with elevations can be found in appendix A.

The conclusions reached

from analysis of these graphs are summarized in Tables 2 and 3 and
are further discussed below.

Individual Causes of Elevated LFTs
CMV:

CMV, both reactivation and primary disease, was the most

common identifiable cause of elevated LFTs in this study.

Of six

azathioprine-treated patients with elevated SGOT and/or SGPT, four
had acute CMV hepatitis as did three out of nine cyclosporine-treated
patients (p = .31).

Conversely, of six azathioprine-treated patients

with CMV infections, four developed hepatitis as did three of ten
cyclosporine-treated patients (p = .3).
All four azathioprine-treated patients with CMV hepatitis and two
of the three cyclosporine-treated patients were symptomatic with a
febrile illness and/or leukopenia.

Cyclosporine patient #7 was an

outpatient during his episode of elevated transaminases and there
were no complaints recorded during any clinic visits.

Despite this,

the peak in his transaminases was so closely related to seroconver¬
sion for CMV that this seems the most likely cause.
Three of the four azathioprine patients (#1,2,4) with CMV
hepatitis were being treated for rejection with ATG during or just
prior to developing CMV.

In none of these patients could use of ATG
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be related to elevated LFTs.

In patients #1 and #4, peak elevations

in LFTs did not occur during ATG treatment.

In patient #2, eleva¬

tions in transaminases did occur only during treatment with ATG.
Although ATG can cause a hypersensitivity type reaction (similar to
serum sickness) and thus could cause elevated LFTs, patient #2 had no
evidence of this.

The patient's fever pre-dated and post-dated ATG

treatment and was probably due to infection with CMV.
In both groups, CMV hepatitis tended to occur between one and
three months post-transplant with elevations in both SGOT and SGPT.
SGPT tended to be greater than SGOT and could rise as high as 300 to
400 IU while SGOT generally peaked between 100 to 200 III.

In both

groups, elevations in SGPT could persist for up to two to three
months.
Cyclosporine-treated patient #9 with symptomatic CMV-hepatitis in
the second and third post-transplant months is described in detail
elsewhere (77) but deserves further comment here.

During the first

post-transplant week, she had an elevated SGOT with normal total and
direct bilirubin while being treated for chest pain in the Coronary
Care Unit.

The patient had a long history of congestive heart

failure which probably accounted for this initial transient elevation
in SGOT.

Later in her post-transplant course, she went on to develop

an intestinal lymphoma which regressed with discontinuation of
cyclosporine (77).

Interestingly, the patient was not seropositive

for EBV yet molecular hybridization studies showed that the tumor
cells contained the EBV genome (77).
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Other Viral/Non A-Non B:

After CMV, the most common cause of

elevated LFTs was a viral illness that could not be identified as CMV
or HBV.

In azathioprine patient #3 and in cyclosporine patient #11,

the elevation was transient while in cyclosporine-treated patients
#14 and #15, the hepatic dysfunction was chronic.
The cause of elevated transaminases in patients #3 and #11 was
designated as other viral because of the temporal association with
fever and leukopenia.
patient.

EBV infection was not ruled out in either

Non A-non B hepatitis could not be definitely ruled out in

patient #11 since the elevation in LFTs preceded the symptoms by 13
days.

Also, the patient's review of systems was positive for

jaundice prior to transplantation.
Cyclosporine-treated patients #14 and #15 had elevations in SGOT
and especially SGPT throughout the follow-up period.
consistent with non A-non B hepatitis.

This pattern is

In patient #14 the initial

increase in SGOT and SGPT was accompanied by a febrile illness which
pre-dated and post-dated ATG therapy for rejection.
Initially his
3
WBC was greater than 20,000 cells/mm but he developed leukopenia
immediately after ATG therapy ended.

There was no evidence of

chronically elevated LFTs prior to transplantation.

Patient #15 had

a post-transplant course complicated by a perforated intestinal
diverticula requiring i1eocolectomy and ileostomy and then further
surgery for intestinal obstruction.

Although the patient had

evidence of sepsis during part of this time, elevated LFTs preceded
these events by many weeks.

The patient also developed
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steroid-induced diabetes mellitus post-transplant, but again elevated
LFTs preceded this.
Sepsis:

Azathioprine-treated patient #6 and cyclosporine-treated

patient #8 had elevated LFTs associated with terminal medical
events.

Patient #6 was a 34 year old male who was admitted for re¬

jection of his living-related renal graft during the fifth post¬
transplant month.

During treatment with monoclonal antibodies

against 0KT3 cells, the patient began a progressive, down-hill course
marked by elevated SGOT and SGPT, a spreading cutaneous herpetic
infection, a question of an infiltrate on chest x-ray, disseminated
intravascular coagulation, and decreasing mental status.

Of note,

the patient was treated with IV acyclovir for disseminated herpes
zoster during the second post-transplant month and previously had an
episode of cutaneous herpes simplex.

Just prior to his demise, blood

cultures were positive for gram negative organisms and CSF was FAMA
positive (indicative of herpetic infection).

Elevated LFTs in this

patient can be attributed to a disseminated herpetic infection with
bacterial sepsis.
Patient #8 was a 32 year old man with brittle insulin-dependent
diabetes mellitus who was admitted during the third post-transplant
month for treatment of rejection and for a left arm abscess.

His

hospital course was marked by sepsis with disseminated intravascular
coagulation and he ultimately died after a hypoglycemic seizure.
Relatively small elevations of SGOT with marked hyperbilirubinemia
during this time were probably due to sepsis.

Earlier solitary
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elevations in SGOT were probably as a result of extremely elevated
blood sugars (generally greater than 700 mg/%).
Mi seel 1aneous:

The remaining two cyclosporine-treated patients

had more than one possible cause for elevated LFTs and each will be
discussed briefly.
Patient #10, a 47 year old black male with a history of
congenital heart disease, had a post-transplant course notable for
several mild elevations (generally less than 60) in SGPT.

During one

elevation the patient presented with ataxia characteristic of
dilantin toxicity and an elevated dilantin level.

Dilantin-induced

hepatitis, however, is usually associated with a hypersensitivity
reaction which this patient did not have (78).

Also, the patient had

persistent elevations in SGPT even after dilantin levels returned to
normal.

Although the patient did have a four-fold rise in his

anti-CMV antibody, the waxing and waning in SGPT is not characteris¬
tic of CMV hepatitis seen in the other patients.

A hepatitis B

screen was not done but the patient was HBV negative pre-transplant
and acute hepatitis B infection does not usually present with mild
chronic elevations in SGPT (79).

This patient also developed steroid

induced diabetes mellitus and could have had elevated LFTs on the
basis of fatty liver.

Chronic elevations in SGPT along with the

patient's history of cardiac surgery and probable transfusions, make
non A-non B hepatitis the most likely possibility.
Patient #12, a 44 year old male, developed transient elevations
in SGOT and SGPT while being treated with ATG in the sixth post¬
transplant month.

The patient had fevers and leukopenia, generally
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but not exclusively associated with ATG therapy.

Concommitantly, he

developed a pulmonary infiltrate, rales, weight gain and pedal edema
which seemed to resolve with Lasix.

Transiently elevated LFTs in

this patient could have been due to cardiac failure but a viral
illness cannot be definitely excluded because of the possibility of a
febrile illness not caused by ATG.

ATG seems to be an uniikely cause

of elevated transaminases in this patient since he had no other signs
of a hypersensitivity reaction.

Comparison of Mean Monthly LFTs
The average SGOT, SGPT and total bilirubin were calculated for
each patient by month and then the means were compared in the
cyclosporine group versus the azathioprine group.

Due to the small

number of patients in each group and the similar frequency of
clinical hepatitis in each group, all patients were included.
Patients could have anywhere from none to 16 determinations for any
given month.

As seen in Figures 1A and IB, there was no significant

difference in SGOT or SGPT between cyclosporine and azathioprine
groups during any post-transplant month.

Total bilirubin (Figure 1C)

tended to be higher in the cyclosporine group and the result was
statistically significant during post-transplant months one and
three.

The higher mean total bilirubin for the azathioprine group in

month 6 is due to patient #6, described previously, who had a mean
bilirubin for that month of 5.46 mg/dl while dying of sepsis.

This

value was five times higher than the other 5 patients and when this
value was excluded, the mean was .79 ± .15 (p = .24) compared with
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the cyclosporine group.

When patients with elevated transaminases

were excluded, the same trends were found.

Correlation of LFTs With Cyclosporine Levels
Mean monthly cyclosporine trough levels were calculated for each
patient and then averaged.

A patient could have any where from none

to 30 determinations for any given month.

As can be seen in Figure

2, cyclosporine levels tended to decline with time, especially after
the first two post-transplant months.

The 9 cyclosporine-treated

patients with liver dysfunction did not have higher serum trough
levels of the drug during any post-transplant month when compared to
patients with normal LFTs (Table 4).
In order to detect a dose-dependent effect of cyclosporine, a
linear regression analysis was used to correlate LFTs with the
cyclosporine trough level measured on the same day.

The data for

direct and total bilirubin is summarized in Table 5.
When all patients were considered (even those with clinical
hepatitis), no correlation was found between cyclosporine trough
levels and either SGOT (r = .04, p = .44), SGPT (r = .001, p = .99),
direct bilirubin (r = .04, p = .60) or total bilirubin (r = .06, p =
.40), when six months of data was examined.

However, a correlation

between direct bilirubin or total bilirubin became apparent when the
first two post-transplant months were analyzed.

This became even

more prominant when those patients with elevated transaminases due to
other causes were excluded.

There was no correlation between

cyclosporine levels and either SGOT or SGPT.
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DISCUSSION
Prior to the cyclosporine era, chronic liver failure was found to
be the most common cause of death in renal transplant recipients with
grafts functioning more than 5 years (52).

Since cyclosporine

therapy has been associated with hepatic dysfunction in some reports,
this study was undertaken to examine the role of cyclosporine in
post-transplant liver disease.
Because of the retrospective nature of this study, LFTs and
particularly bilirubin levels, were not obtained regularly.

As a

general rule, once patients were discharged from the hospital, LFTs
were measured more frequently when patients became symptomatic.
Since liver dysfunction can be entirely asymptomatic, the potential
for an artificially low incidence of liver disease existed.

This was

especially true for azathioprine-treated patients who had fewer LFTs
measured.

We attempted to minimize this detection bias by excluding

patients with an insufficient number of LFTs.

This resulted in a

small sample size which should be kept in mind when considering these
results.
The issue of cyclosporine hepatotoxicity was addressed in two
ways.

In the first part of this study the incidence and causes of

elevated transaminases were compared in cyclosporine-treated patients
versus azathioprine-treated patients.

This type of comparison might

have allowed us to detect a subtle effect of cyclosporine in
influencing liver disease.

Our results show, however, that there is

no difference in the incidence of liver dysfunction between the
cyclosporine group (47%) and the azathioprine group (40%).

- 39 -

Furthermore, a careful analysis of all available data revealed an
identifiable etiology in each case of elevated transaminases.

In the

cyclosporine group, cyclosporine dosages were not adjusted in
response to elevated LFTs and in no case could cyclosporine be
implicated as the cause of hepatic dysfunction.

Despite small

numbers, it appeared that the causes of hepatitis were no different
in cyclosporine-treated patients versus azathioprine-treated
patients.

If both groups are considered together, our results are

similar to those of other authors studying the causes of
post-transplant hepatitis.
In this series, as in others, HBsAg negative, viral hepatitis was
the most common cause of elevated LFTs (51,62,63,65,66).

In fact, in

no patient could HBV be implicated as the cause of liver
dysfunction.

Although HAV was seldom tested for, other authors have

found that HAV plays no role in post-transplant hepatitis (51,62).
Of 12 patients with viral hepatitis CMV infection was the most
commonly identifiable cause (7 patients) of acutely elevated
transaminases.

CMV hepatitis always occurred within the first three

post-transplant months and elevated LFTs could persist for up to
three months.

These characteristics are similar to those reported

previously (51,56,62,63,64,65).

The contributing role of other

herpes viruses in these patients cannot be ruled out.

As pointed out

by Marker et al. and Balfour et al., seroconversion for EBV, HSV or
HZV often accompanies active CMV infection (67,74).

Unfortunately

none of these viruses was tested for on a routine basis.
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Two additional patients had a viral syndrome characterized by
transient elevations in transaminases with leukopenia and/or fever
that could not be identified as CMV or HBV.

As stated above,

serologic tests for viruses such as EBV, HSV or HZV were not
routinely obtained, thus these viruses could not be definitively
ruled out as etiologic agents.

Despite this, most studies have found

that herpes viruses (other than CMV) play a minor role in
post-transplant liver disease (62,63,64,66).

In this study, only one

patient developed a fulminant, disseminated herpetic infection with
accompanying hepatitis (and bacterial sepsis).

This type of course

in renal transplant recipients with HSV or HZV has been reported
previously (50,54,62,63,66).
In at least two patients, hepatic dysfunction was of a chronic
nature and transfusion associated non A-non B hepatitis was the most
likely cause.

With a longer follow-up period, this diagnosis might

have been possible in other patients as well, especially since other
studies have implicated non A-non B hepatitis as the most frequent
cause of chronic liver dysfunction after renal transplantation
(51,53,62,66).
In addition to cyclosporine and for that matter azathioprine,
patients in this study were on a variety of drugs with hepatotoxic
potential including ATG, dilantin, hydralazine, alpha-methyldopa and
furosemide.

Drug dosages were not adjusted in response to LFTs and

in most patients this did not affect the course of hepatic
dysfunction.

One patient (#10) did present with ataxia due to

dilantin toxicity and shortly thereafter with elevated transaminases

\
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as well.

Nevertheless, dilantin was probably not the cause of

hepatic dysfunction in this patient.

He had been on dilantin for

many years without any history of liver dysfunction and his
transaminases were elevated even after dilantin levels returned to
normal.

Also, dilantin hepatotoxicity is usually due to a

hypersensitivity reaction which this patient did not have.

In

addition, several patients were treated with ATG during periods of
abnormal liver function.

In all but one of these patients (#12) a

viral cause (CMV) of hepatitis was identified.

ATG can cause

elevated LFTs on the basis of a hypersensitivity reaction akin to
serum sickness.

None of these patients, however, had any other signs

of this type of reaction.

Our results are thus in agreement with

those of other published reports showing that medications play only a
very minor role in liver disease after renal transplantation
(51,62,63,65,66,69).
In sum, cyclosporine does not appear to alter the spectrum of
liver disease in patients receiving renal allografts.

The type of

analysis described above highlights the complexity involved in
assigning an etiology to post-transplant liver dysfunction.
Cyclosporine hepatotoxicity was examined in another type of
analysis.

Mean monthly LFTs were compared in cyclosporine- versus

azathioprine-treated patients and an attempt was made to correlate
serum cyclosporine trough levels with LFTs.

Cyclosporine levels were

measured using the HPLC method which is thought to be more reliable
in the setting of liver dysfunction (15).

All determinations were

performed on serum which may more accurately reflect free drug levels
(16).
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Not surprisingly, no association was found between transaminase
levels and cyclosporine therapy.

The 9 cyclosporine-treated patients

with elevated LFTs did not have higher cyclosporine levels during any
post-transplant month when compared with those patients having normal
LFTs.

Nor was there any consistent difference in mean monthly SGOT

or SGPT in the cyclosporine group versus the azathioprine group.
Finally, serum cyclosporine levels could not be correlated with SGOT
or SGPT using a linear regression analysis even when the 9 patients
with other causes for elevated transaminases were excluded.
Although clinical hyperbilirubinemia in the absence of elevated
transaminases did not occur, there was evidence of subclinical
hepatic dysfunction in cyclosporine-treated patients.

Total serum

bilirubin levels were higher (though still within the normal range)
in cyclosporine-treated patients versus azathioprine-treated patients
during the early post-transplant months.

The difference was

statistically significant during months 1 and 3.

Furthermore,

cyclosporine levels were correlated with both direct bilirubin and
total bilirubin during the first two post-transplant months when
cyclosporine trough levels were highest.

The correlation became

stronger when the 9 patients with other causes for elevated LFTs were
excluded.
Although the correlation of direct bilirubin with cyclosporine
levels is suggestive of decreased bile flow, it is important to
distinguish between isolated hyperbilirubinemia and true cholesta¬
sis.

In this study the specific tests needed to clarify this point -

AP (liver isoenzyme), 5'-nucleotidase, gammaglutamyl transpeptidase
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or serum bile acid levels - were not obtained and further work is
needed in this regard.

The reports of several authors, however, have

addressed this issue.

Rotolo et al., studying isolated, perfused rat

livers, found that cyclosporine in doses of 2 mg/kg and 20 mg/kg
decreased bile flow and bile acid secretion (80).

Schade et al.

prospectively measured fasting bile salt levels in 11 cyclosporinetreated heart transplant recipients and found them to be markedly
elevated despite normal AP levels (48).

Finally, Lorber et al. noted

an increased incidence of cholelithiasis in cyclosporine-treated
patients compared with azathioprine-treated patients (47).

From

these data it seems that hyperbilirubinemia in cyclosporine-treated
patients is probably indicative of true cholestasis.
Our findings with regard to hyperbilirubinemia are similar to
those of other authors in that a relationship between cyclosporine
blood levels and serum bilirubin levels was detected in the early
post-transplant period (9,39,43, 49).

The magnitude of hyperbili¬

rubinemia, however, was not the same.

For example, Laupacis, et al .,

Klintmalm, et al., and Keown, et al., all found that between 8.3% and
19.6% of their cyclosporine-treated patients developed overt
hyperbilirubinemia usually within the first post-transplant month
(9,39,41,42,43).

There are several possible explanations as to why

overt hyperbilirubinemia was not detected in this study.

First, most

of the hepatotoxic effects of cyclosporine have been observed early.
Lorber, et al., reported that 61% of such episodes began during the
first post-transplant week (47).

Since bilirubin levels were not

measured regularly, it is possible that this effect was missed.
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Alternatively, cyclosporine levels at this institution were kept
quite low.

Even during the first post-transplant month the mean

cyclosporine level was only 121 ± 15 ng/ml.

Although it is difficult

to compare because other centers used the RIA technique, serum
cyclosporine trough levels in other studies were generally kept
between 100 and 400 ng/ml with levels rising above 600 ng/ml during
hepatotoxic episodes (39,41,43).

Hyperbilirubinemia may have been

avoided at this center by keeping cyclosporine levels low.

Further

support for this theory comes from the University of Minnesota where
cyclosporine levels were kept between 100 and 200 ng/ml

(HPLC).

These authors found no increase in the incidence of hyperbili¬
rubinemia in cyclosporine-treated patients versus azathioprinetreated patients (19).
Despite these differences, findings from this study and others
suggest that serum bilirubin levels (and not transaminases) are the
more important parameter in detecting cyclosporine hepatotoxicity
(39,42,44,45,48).

Only Maddux, et al., and Lorber, et al. have

reported that cyclosporine immunosuppressive therapy is associated
with elevated transaminases (46,47).

In the two types of analyses

described above we could find no evidence for this association.

In

this study, every instance of elevated transaminases was analyzed in
an depth manner with a review of all clinical and viral data
available.
identified.

In every case an etiology other than cyclosporine was
Furthermore, there was no correlation between serum

cyclosporine levels and transaminases.

McMaster, et al., who

undertook a similar type of analysis, obtained the same results.

Not
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only was there was no difference in the incidence of elevated LFTs in
cyclosporine-treated patients versus azathioprine-treated patients,
but a careful review revealed that, as in the series reported here,
infection was the most common cause of liver dysfunction in both
groups.

Both Maddux et al., and Lorber et al. do state that patients

with other causes of hepatitis were excluded.

Given the complexity

of this issue, however, the details of this process were not
adequately described.

For example, Lorber et al. report that 49% of

466 patients developed cyclosporine hepatotoxicity.

With the

ubiquity of CMV it would be surprising if CMV infection were absent
in this large a proportion of renal transplant recipients.
Additional information would be essential in deciding whether all
cases of elevated LFTs in this study were in fact due to
cyclosporine.
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CONCLUSION
In sum, cyclosporine appears to play a minor role in the genesis
of liver disease after renal transplantation.

Neither the frequency

nor the causes of elevated transaminases differs between
cyclosporine-treated patients and azathioprine-treated patients.
Mean levels of SGOT and SGPT are not significantly higher in
cyclosporine-treated patients and there is no correlation between
either enzyme and cyclosporine trough levels.

Elevated transaminases

do not appear to be a specific marker for cyclosporine hepatotoxicity
but rather due to viral hepatitis which is prevalent after renal
transplantation.
The fact that bilirubin levels are higher (though still within
the normal range) in cyclosporine-treated patients versus
azathioprine-treated patients during the first few post-transplant
months does, however, suggest that the drug can cause mild cholesta¬
tic hepatic dysfunction.

This is further supported by a correlation

between cyclosporine trough levels and direct and total bilirubin
levels.

It is possible that when mean serum cyclosporine trough

levels are kept well under 200 ng/ml, as in this study, this is of
little clinical significance since bilirubin levels remain within the
normal range.
The advent of cyclosporine has not changed the characteristics of
post-transplant liver disease that existed in the azathioprine era.
Viral hepatitis is still the most common cause of abnormal liver
function in renal transplant recipients treated with either cyclo¬
sporine or azathioprine.
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TABLES AND FIGURES
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TABLE 1
BASELINE CHARACTERISTICS

Cyclosporine

Azathioprine

19

15

47±2

35±2

26

13

.43

100

47

< .0004

% First Renal Transplant

84

87

1.00

6 Month Graft Survival

89

100

.49

89

100

.49

84

93

.61

89

93

1.00

Total Number of Patients
Mean Age (years)
% with Diabetes
% Cadaveric Transplant

(%)

6 Month Patient Survival
12 Month Graft Survival

(%)
(%)

12 Month Patient Survival

(%)

P Value

.0008
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TABLE 4

MEAN MONTHLY CYCLOSPORINE LEVELS IN
PATIENTS WITH ELEVATED VS. NORMAL TRANSAMINASES

Post-transplant
Month

Elevated
Transaminases
(n = #
of patients)

Normal
Transaminases
(n = #
of patients)

P Vali

1

108 ± 22
(9)

133 ± 19
(10)

.41

2

114 ± 30
(9)

97 ± 12
(10)

.60

3

78 ± 9
(9)

72 ± 8
(10)

.59

4

53 ± 6
(9)

62 ± 11
(10)

.50

5

77 ± 14
(6)

84 ± 14
(10)

.74

6

75 ± 11
(4)

88 ± 21
(8)

.68
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TABLE 5

CORRELATION OF CYCLOSPORINE LEVELS WITH
DIRECT AND TOTAL BILIRUBIN LEVELS

Direct Bi1irubin

Total Bilirubin

All patients
(2 months of data)

r = .40, p < .001

r = .30, p = .001

All patients
(6 months of data)

r = .04, p .60

r = .06, p = .40

Patients with normal
transaminases
(2 months of data)

r = .74, p < .001

r = .41, p = .003

Patients with normal
transaminases
(6 months of data)

r = .64, p = .0001

r = .34, p = .008
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Figure 1:

Mean Monthly LFTs in Cyclosporine-Treated Patients Vs
Azathioprine-Treated Patients.
An average monthly SGOT (A), SGPT (B) or total bilirubin
(C) level was calculated for each patient (N). There were
anywhere from 2 to 16 monthly determinations for each
patient. The mean value + SEM for each month was compared
in the cyclosporine group (A —A ) versus the
azathioprine group (q-□ ):
P < .05

MEAN SGOT IU/ML
10

20

30

40

50

150

TOTAL BILIRUBIN MG/DL

0.5

1

1.5

2

2.5
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Figure 2:

Mean Monthly Cyclosporine Trough Levels.
Cyclosporine trough levels were measured on serum using
High-Performance Liquid Chromatography. An average
monthly cyclosporine trough level was calcualted for each
patient (N). There were anywhere from 2 to 30 monthly
determinations for each patient. Mean ± SEM cyclosporine
trough levels during post-transplant months 2, 3, 4, 5 and
6 were compared with the level during month 1.

CYLCOSPORINE TROUGH LEVEL(ng/ml)

60

80

100

120

140

MEAN MONTHLY CYCLOSPORINE TROUGH LEVELS
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APPENDIX:

Clinical Data for Nine Cyclosporine-Treated Patients and
Six Azathioprine-Treated Patients with Elevated
Transaminases.

56 -

LEGEND:

D-O-D

: SGOT
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: SGPT
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Cytomegalovirus Serology

HBV:

Hepatitis B Virus Serology

EBV:

Epstein-Barr Virus Serology
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U:
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S:

Saliva
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Cytomegalovirus Cultures

Pretransplant

MCA:

Ortho monoclonal antibodies
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Right lower lobe

L:

Left

Wgt:

Weight

Cxr:

Chest x-ray
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CYCLOSPORINE:PATIENT NUMBER EIGHT
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SGOT/SGPT IU/ML
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0

CYCLOSPORINE:PATIENT NUMBER NINE

DAY POST TRANSPLANT

SGOT/SGPT IU/ML

CYCLOSPORINE:PATIENT NUMBER TEN
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0

CYCLOSPORINE:PATIENT NUMBER ELEVEN
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